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The present review aims at summarizing the major therapeutic roles of resveratrol and 
omega-3 fatty acids (O3FAs) along with their related pathways. This article reviews 
some of the key studies involving the health benefits of resveratrol and O3FAs. Oxidative 
stress has been considered as one of the most important pathophysiological factors 
associated with various cardiovascular disease conditions. Resveratrol, with the potent 
antioxidant and free radical scavenging properties, has been proven to be a significantly 
protective compound in restoring the normal cardiac health. A plethora of research also 
demonstrated the reduction of the risk of coronary heart disease, hypertension, and 
stroke, and their complications by O3FAs derived from fish and fish oils. This review 
describes the potential cardioprotective role of resveratrol and O3FAs in ameliorating the 
endoplasmic reticulum stress.
Keywords: resveratrol, omega-3 fatty acid, oxidative stress, endoplasmic reticulum stress, cardiovascular 
diseases, coronary artery diseases
inTRODUCTiOn
Cardiovascular complications continue to be among the list of leading causes of death worldwide. 
According to centers for disease control and prevention (CDC) reports, more than half a million 
people in the USA die of heart disease every year, one in every four deaths every year (1). Increasing 
evidences suggest that metabolic syndrome constitutes a significant risk for cardiovascular diseases, 
which can also cause type 2 diabetes, obesity, and oxidative stress (2, 3). Effective tactics to reduce 
these conditions include immediate weight loss (4), and long-term dietary strategies enhancing 
health by maintaining the body weight (5). There are multiple non-pharmacological approaches, 
such as alternative medicine, that have the potential to reduce cardiovascular risks; resveratrol and 
omega-3 fatty acid (O3FA) are two well-known natural products that come under this category.
Resveratrol is chemically trans-3,5,4′-trihydroxystilbene. It is a polyphenol phytoalexin compound 
naturally abundant in a variety of plant species, including white hellebore (Veratrum grandiflorum O. 
Loes), Japanese knotweed (Polygonum cuspidatum), grapes, blueberries, peanuts, wine, and mulber-
ries (6, 7). Resveratrol came into the limelight following the discovery of the cardioprotective nature 
of red wine (8). This has paved the way for new research activities involving clinical health benefits 
of resveratrol. A growing body of research therefore indicated that resveratrol could improve a wide 
variety of disease conditions, including cardiovascular diseases, cancer, ischemic disorders, and neu-
rodegenerative disorders (9). It is also postulated that resveratrol can increase the stress resistance 
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and also slow down the aging process to increase the life span in 
diverse organisms from microorganisms to vertebrates (6).
Resveratrol is one of the well-known natural compounds, 
which is well-studied for its free radical scavenger and antioxidant 
properties. It can modulate various intracellular signal transduc-
tion pathways and demonstrate therapeutic effects, including 
cell survival, modulation of apoptosis, and angiogenesis (10, 11). 
Growing evidences suggests the anti-cancer activity of resveratrol 
and its potential as a therapeutic as well as a chemo-preventive 
agent (12). Scientific outcomes demonstrated the potential use 
of resveratrol in various cancers (13–25). However, pre-clinical 
results were not well reflected in clinical studies in human. It may 
be due to the pharmacokinetic issues pertaining to resveratrol. It 
is lipophilic in nature and has a short half-life as well.
The use of O3FAs as a widespread alternative has been prac-
ticed globally by many societies. O3FAs are essential for normal 
growth and development of the nervous system. The benefits of 
O3FA have been documented in the past 35 years (26–28). All 
these research data strongly support the use of O3FAs in reducing 
the risk of cardiac diseases.
The purpose of this review is to summarize the major anti-
oxidant role of resveratrol and O3FA along with their related 
pathways and highlight promising therapeutic approaches. The 
benefits of combinational therapy with these two natural com-
pounds were also discussed.
ReSveRATROL AnD THe enDOPLASMiC 
ReTiCULUM STReSS
The endoplasmic reticulum (ER) is a significant but complex 
intracellular organelle in the physiological system. It is a vital 
organelle involved in modification and synthesis of proteins, 
translational processes, and fabrication at the post-translational 
level. Physiologically, the integrity of ER is maintained for proper 
cellular functioning. Any stimuli from diverse origin can influ-
ence the ER environment and generate disturbance in terms of 
nutritional deficiency leading to a compromised pathological 
status. The stimuli can be of physiological and biochemical origin, 
which can produce moderate-to-severe abnormalities, including 
alterations in glycosylation, depletion of calcium stores, oxidative 
stress conditions, DNA damage, and other pathological condi-
tions. These alternations generally produce a severe pathological 
stress condition in the ER known as ER stress or ER oxidative 
stress. This pathological stress is coexisted with the abnormal 
protein accumulations in the ER.
Many reports from animal and human studies have shown 
that oxygen deprivation in the heart causes ER stress of myocytes 
by accumulating unfolded and misfolded proteins, thereby trig-
gering apoptosis (29–32). Also, the research data showed that ER 
stress may play a crucial role in the elevation of atherosclerotic 
plaque (33–35). Furthermore, recent evidences also suggest that 
a transcriptional factor, nuclear factor-E2-related factor (Nrf2), 
may play a central role to compensate ER stress conditions 
(36). This Nrf2 signaling has shown to upregulate the expres-
sion of proteasomal catalytic sub-units in several cell types, 
thereby contributing to the ER stress response by enhancing 
proteasomal-mediated ER-associated degradation (37). Other 
studies also suggest that interventions against ER stress and 
activation of Nrf2 significantly reduce myocardial infarct size in 
animals exposed to I/R injury and also reduce cardiac hypertro-
phy in heart failure animal models (38).
ReSveRATROL AS A 
CARDiOPROTeCTive AGenT
Resveratrol has shown beneficial and protective effects against 
most degenerative and cardiovascular diseases, including 
ischemia/reperfusion injury, atherosclerosis, hyperten-
sion, and heart failure. The adaptive response through the 
preconditioning-like action of resveratrol is linked with the 
cardioprotective effects of the compound. With the expression 
of cardioprotective genes and proteins, such as heat shock and 
antioxidant proteins, resveratrol demonstrated an adaptive 
stress response as the preconditioning (39). These effects of 
resveratrol have been correlated with the modulation of mTOR-
Rictor survival pathways (40). Results of several in  vitro and 
in vivo studies of resveratrol in animal models suggested LDL 
oxidation inhibition, suppression of aggregation of platelets, 
and reduction of ischemia–reperfusion-induced myocardial 
injury, which in turn indicated the promising cardiovascular 
protective effects of resveratrol (41–43). Resveratrol also 
revealed anti-inflammatory activity, which was postulated to 
be linked with nitric oxide (NO) production. This study also 
demonstrated cardioprotective action of resveratrol by inhibit-
ing toll-like receptor 4 (TLR4)/NF-κB signaling pathway in a 
rat model of myocardial ischemia and reperfusion (MI/R) (44). 
Another very common cardiovascular disease is stroke, which 
is one of the main causative factors of deaths throughout the 
world population. Scientific investigations suggest oxidative 
stress as the predominant pathophysiological modality associ-
ated with stroke (45, 46). Recent data also suggest that the ability 
of resveratrol in ameliorating the oxidative stress conditions 
might be due to the aggravation of NO production along with its 
anti-inflammatory activity (47). Studies also suggested several 
mechanisms of action for resveratrol to justify its cardioprotec-
tive actions (48, 49). Resveratrol was also found to be protective 
against the cardio toxicity induced by the potent anti-cancer 
agent doxorubicin (50). These authors showed that resveratrol 
restored the mitochondrial structure as evident from the elec-
tron microscope examinations. A recent pre-clinical study also 
suggested that resveratrol alleviate the cardio toxicity induced 
by doxorubicin (51).
ROLe OF OMeGA-3 FATTY ACiDS AS 
AnTiOXiDAnT AGenTS in 
CARDiOvASCULAR DiSeASeS
Two well-known fish/fish oil-derived O3FA are the eicosapen-
tanoic acid (EPA) and docosahexanoic acid (DHA). DHA and 
EPA are vital nutrients required for brain and retina growth in 
order to have normal neuronal functioning and vision. These two 
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in turn help humans develop their learning and mental abilities 
throughout life. These fatty acids are by-products derived from 
the metabolic conversion of the amino acid alanine (ALA) in 
the liver (52). Yet, human intake of O3FA is limited; they are not 
abundant in vegetables and grain food sources, and thus, they 
have to be supplemented directly. In addition, the metabolic 
change of alanine (ALA) to DHA/EPA in the body is limited; 
therefore, it is recommended to have sufficient amounts of fish, 
or O3FA directly as a dietary supplement.
The American Heart Association recommends 130  mg/day 
of DHA/EPA (combined), for people suffering from coronary 
heart disease. Various studies have indicated the benefits of fish 
consumption containing the O3FA, EPA/DHA, and lowering the 
risk of cardiovascular conditions, such as fatal heart attack, high 
cholesterol, and stroke (53–57). Yet, the signal transduction path-
ways and mechanisms associated with it and how they function 
have not fully been revealed.
MeCHAniSMS ASSOCiATeD wiTH O3FA
Omega-3 fatty acids seem to have versatile properties with 
no significant drug interactions. The suggested mechanisms 
associated with the benefits of O3FA are stabilization of plaque 
formation, improving lipid profile, normalizing blood pressure, 
and anti-inflammatory and anti-arrhythmic properties (58). 
Nevertheless, there is still a major controversy over O3FA having 
benefits against arrhythmias, which was suggested by the Italian 
GISSI-Prevenzione study (59). The exact mechanism of its action 
in reducing cardiovascular risk is yet to be understood.
O3FA AnD OXiDATive STReSS
One of the valuable properties of O3FAs is their antioxidative 
action. They seem to induce cardioprotection by ameliorating 
oxidative stress. Oxidative stress causes damage by the produc-
tion of radicals that distress normal metabolic cell functioning 
by destroying lipids, proteins, and nucleic acids. Radical accu-
mulation eventually causes structural cell membrane damage, 
vascular endothelial dysfunction, and cell death, often leading 
to cardiovascular diseases (60). A recent study in rats evaluated 
the combined effects of intermittent hypobaric hypoxia (IH) 
and O3FA on cardiac function, oxidative balance, and inflam-
matory state. Their findings showed that animals under IH have 
improved left ventricular function, reduced oxidative stress, 
and increased antioxidant enzyme expression when compared 
to the normobaric normoxia group. Supplementation of O3FA 
showed similar results to that of the IH group, suggesting that 
both conditions, IH and O3FA, induce functional improvement 
by antioxidant and anti-inflammatory mechanisms, thereby 
establishing cardioprotection (61).
Furthermore, another protective action of O3FA is to reinforce 
the body’s antioxidant defenses to improve cardiac function. 
Recent data suggest that DHA and EPA regulate cell membrane 
fluidity, organization, and permeability that affect signaling 
pathways and diffusion processes, with positive effects on key 
cardiovascular pathways (62). In addition, O3FAs manage to 
exert anti-inflammatory properties by controlling the synthesis 
of immune mediators (e.g., thromboxanes, prostaglandins, and 
leukotrienes) in murine cell lines and human primary monocyte-
derived macrophages (63–65). These mediator molecules change 
the arachidonic acid metabolic pathway of prostaglandin E2 
(PGE2), via the activation of cytosolic phospholipase A2 (cPLA2), 
cyclooxygenase 2 (COX-2), and the production of PGE2, as a 
cPLA2 inhibitor, and reduce other pro-inflammatory molecules 
in the heart (e.g., IL-1 and IL-6) (63). Also, a high O3FA enriched 
diet has shown benefits in a rat model with cardiac ischemia–rep-
erfusion injury (66).
Furthermore, specific types of O3FAs can affect oxidative 
stress due to disparities in their chemical predisposition to 
oxidation. Experiments by Bellido et al. (67) showed an increase 
in activation of a redox-sensitive transcriptional factor, NF-κB, 
in peripheral blood mononuclear cells following a meal high in 
butter or walnuts but not olive oil (67). These experiments are 
interesting and require further expansion to determine specific 
fatty acid effects, and any other meals specifically enriched with 
O3FA.
ReSveRATROL AnD O3FA COMBineD 
eFFeCT
Many in vivo and in vitro studies testing the combined effects of 
O3FA and resveratrol have shown them to have synergistic effects 
on inflammation. For example, a recent study by Schwager et al. 
(68) showed that the LPS-stimulated peripheral leukocytes and 
IL-1-activated human chondrocytes treated only with resveratrol 
significantly reduced levels of prostaglandin 2 (PGE2), CCL5/
RANTES, and CXCL8/IL-8, but increased IL-1β, IL-6, and 
IL-10, whereas O3FA treatment increased the levels of PGE2 
and CXCL8/IL-8. Surprisingly, their combined administration 
exerted joint effects on CCL5/RANTES and IL-6 or CXCL8/IL-8 
(68). Thus, O3FA and resveratrol act together on inflammatory 
mediators when dealing with acute and chronic inflammation 
of chondrocytes, but not on acute inflammation of peripheral 
leukocytes. In diseases where chronic inflammation occurs, 
such as osteoarthritis, O3FA and resveratrol may be beneficial. 
In vitro studies of chronic inflammation implementing long-term 
treatment of these two have shown a reduction in the production 
of inflammatory mediators. For example, bovine chondrocytes 
and cartilage explants have identified that long-term in  vitro 
treatment of chondrocytes with conjugated linoleic acids or EPA 
mitigated the production of PGE2 and nitric oxide (69). Also, 
other studies reported reduced mRNA levels of matrix metal-
loproteinaises (MMPs), a disintegrin and metalloproteinase with 
thrombospondin motifs 4 (ADAMTS-4), and interleukins (68, 
70). Thus, resveratrol and O3FA are able to reduce the inflamma-
tory processes during chronic inflammation. But, in instances of 
acute inflammation, resveratrol acts to reduce early inflamma-
tory events, whereas O3FA has the opposite effect and increases 
inflammatory events.
In an attempt to identify an effective therapy for car-
diovascular patients, Hobbs et  al. (71) did a pilot study with a 
multi-ingredient supplement (MIS) featuring blend of red yeast 
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rice, bioflavonoids, polycosanol, and resveratrol along with a 
high-potency omega-3 polyunsaturated fatty acid in 19 patients 
with hypercholesterolemia (71). They found that the MIS sup-
plement offers a promising result for cholesterol management 
by decreasing total cholesterol and LDL significantly. A separate 
review by the World Health Organization (72) found that the 
Mediterranean diet (MeDi) is a promising strategy to prevent 
diseases such as cerebro- and cardiovascular diseases, cancer, 
respiratory diseases, diabetes, and neurodegenerative diseases, 
thereby improving life quality (72). The two major components 
in MeDi in this study are long-chain O3FAs derived from fish 
and resveratrol from plant phenols. The MeDi benefits have been 
studied in many human epidemiological studies suffering from 
cancer, cardiovascular conditions (myocardial infarction, stroke, 
angina pectoris, coronary bypass, and coronary angioplasty), and 
neurodegenerative diseases such as Alzheimer’s disease (AD) 
(73–76). Also, a recent long-term randomized clinical trial (RCT) 
in 334 participants with high cardiovascular risk at a mean age of 
67 years (PREDIMED study) reported positive effects of MeDi 
(77, 78).
From these studies, it is evident that the combinational therapy 
with O3FAs and resveratrol is more beneficial, and therefore, 
more studies should be directed to understand more insight on 
their mechanism of action at a molecular level.
COnCLUSiOn
Based on the existing literature discussed in this review, it is evi-
dent that resveratrol and O3FAs are reported to be significantly 
protective and play crucial roles in the prevention of not only vari-
ous cardiovascular diseases but also a variety of other diseases, 
including Alzheimer disease, cancer, diabetes, and inflammation 
(Figure 1). Resveratrol and O3FAs, with their unique antioxidant 
properties and cardioprotective nature, are demonstrated to be 
highly functional and beneficial ingredients in various functional 
foods, although the number of studies in terms of dosage regimens 
and pharmacokinetics profiles of these ingredients is scanty and 
newer studies should be initiated to profile the same. The growing 
body of scientific literatures indicated the potential health benefits 
of these functional ingredients. However, new mechanistic stud-
ies should be designed to evaluate and identify the mechanisms 
behind the observed fascinating beneficial outcomes of resveratrol 
and O3FAs along with their combinational benefits.
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FiGURe 1 | Mechanisms of action of omega-3 fatty acid and resveratrol. Two natural cardioprotective compounds act independently via different pathways 
combination of both may offer beneficial effects. PGG2, prostaglandin G2; PGH2, prostaglandin H2; PGI2, prostaglandin I2 or prostacyclin; eNOS, endothelial nitric 
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